BRPI0716317A8 - método para reduzir a absorção de fosfato em um indivíduo animal humano ou não-humano e método para reduzir a absorção de fosfato em um indivíduo humano - Google Patents

método para reduzir a absorção de fosfato em um indivíduo animal humano ou não-humano e método para reduzir a absorção de fosfato em um indivíduo humano

Info

Publication number
BRPI0716317A8
BRPI0716317A8 BRPI0716317A BRPI0716317A BRPI0716317A8 BR PI0716317 A8 BRPI0716317 A8 BR PI0716317A8 BR PI0716317 A BRPI0716317 A BR PI0716317A BR PI0716317 A BRPI0716317 A BR PI0716317A BR PI0716317 A8 BRPI0716317 A8 BR PI0716317A8
Authority
BR
Brazil
Prior art keywords
human
individual
phosphate absorption
reducing phosphate
reducing
Prior art date
Application number
BRPI0716317A
Other languages
English (en)
Inventor
Helving Christian
Hellestad Erica
Crawford Keith
Cook Mark
Petrovich Martin
Original Assignee
Aovatechnologies Inc
Winsconsin Alumni Res Foundation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aovatechnologies Inc, Winsconsin Alumni Res Foundation filed Critical Aovatechnologies Inc
Publication of BRPI0716317A2 publication Critical patent/BRPI0716317A2/pt
Publication of BRPI0716317A8 publication Critical patent/BRPI0716317A8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/23—Immunoglobulins specific features characterized by taxonomic origin from birds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

método para reduzir a absorção de fosfato em um indivíduo animal humano ou não-humano e método para reduzir a absorção de fosfato em um indivíduo humano trata- se de um método para reduzir a absorção de fosfato em um indivíduo animal humano ou não-humano em que o indivíduo consome uma dieta que contém ácido fítico ou fitato e tem ou está correndo o risco de desenvolver hiperfosfatomia. o método inclui a etapa de administração oral ao indivíduo de um anticorpo de fosfatase alcalina antiintestinal em uma quantidade eficaz para reduzir ou manter a concentração de fosfato de soro no indivíduo.
BRPI0716317A 2006-10-26 2007-10-23 método para reduzir a absorção de fosfato em um indivíduo animal humano ou não-humano e método para reduzir a absorção de fosfato em um indivíduo humano BRPI0716317A8 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85455006P 2006-10-26 2006-10-26
PCT/US2007/082244 WO2008051977A2 (en) 2006-10-26 2007-10-23 Methods of reducing phosphate absorption

Publications (2)

Publication Number Publication Date
BRPI0716317A2 BRPI0716317A2 (pt) 2014-02-25
BRPI0716317A8 true BRPI0716317A8 (pt) 2019-02-05

Family

ID=38983491

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0716320-7A2A BRPI0716320A2 (pt) 2006-10-26 2007-10-23 Método para reduzir a absorção de fosfato em um individuo animal humano e não- humano e método para reduzir a absorção de fosfato em um individuo humano
BRPI0716317A BRPI0716317A8 (pt) 2006-10-26 2007-10-23 método para reduzir a absorção de fosfato em um indivíduo animal humano ou não-humano e método para reduzir a absorção de fosfato em um indivíduo humano

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0716320-7A2A BRPI0716320A2 (pt) 2006-10-26 2007-10-23 Método para reduzir a absorção de fosfato em um individuo animal humano e não- humano e método para reduzir a absorção de fosfato em um individuo humano

Country Status (8)

Country Link
US (2) US8877198B2 (pt)
EP (2) EP2076543B1 (pt)
JP (3) JP5701504B2 (pt)
CN (2) CN101583627A (pt)
AU (2) AU2007325459A1 (pt)
BR (2) BRPI0716320A2 (pt)
CA (2) CA2667563A1 (pt)
WO (2) WO2008067084A2 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0716319A8 (pt) 2006-10-25 2019-02-05 Aovatechnologies Inc método para reduzir a absorção de fosfato em um indivíduo animal humano ou não-humano correndo o risco de desenvolver ou que desenvolveu hiperfosfatomia e método para reduzir os efeitos colaterais da terapia de vitamina d em um ser humano
CA2667563A1 (en) * 2006-10-26 2008-05-02 Wisconsin Alumni Research Foundation Methods of reducing phosphate absorption
JP2012505728A (ja) * 2008-10-17 2012-03-08 フレゼニウス メディカル ケア ホールディングス インコーポレイテッド 透析患者のためのリン結合剤投与量の決定方法
EP3556398A1 (en) * 2018-04-16 2019-10-23 Croda Denmark A/S Phytates for use as a biomolecules delivery or adsorption system

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3689717T2 (de) 1985-11-25 1994-10-20 Ghen Corp Einen spezifischen Antikörper enthaltender Stoff aus Eiern, Verfahren zu dessen Herstellung und seine Anwendung.
US5496545A (en) 1993-08-11 1996-03-05 Geltex Pharmaceuticals, Inc. Phosphate-binding polymers for oral administration
WO1995019373A1 (en) 1994-01-13 1995-07-20 The Board Of Governors For Higher Education, State Of Rhode Island And Providence Plantations Antibodies specific for d-myo-inositol 1,4,5-trisphosphate
KR100406912B1 (ko) 1994-08-05 2004-02-18 위스콘신 얼럼나이 리서어치 화운데이션 사료효율을향상시키기위하여사용되는cck항체
ES2162658T3 (es) 1996-03-05 2002-01-01 Mitsubishi Chem Corp Utilizacion de resinas intercambiadoras anionicas para la fabricacion de un medicamento destinado al tratamiento de la hiperfosfatemia.
CA2261750A1 (en) 1996-07-19 1998-01-29 Nikken Chemicals Co., Ltd. Remedies for hyperphosphatemia
US6423754B1 (en) 1997-06-18 2002-07-23 Geltex Pharmaceuticals, Inc. Method for treating hypercholesterolemia with polyallylamine polymers
US5985938A (en) 1997-11-05 1999-11-16 Geltex Pharmaceuticals, Inc. Method for reducing oxalate
CH694588A5 (de) 1999-02-09 2005-04-15 Hoffmann La Roche Menschliche intestinale Npt2B.
US6213930B1 (en) 1999-03-15 2001-04-10 Wisconsin Alumni Research Foundation Method of using anti-phospholipase A2 antibodies to enhance growth or improve feed efficiency
US6346247B1 (en) * 1999-10-28 2002-02-12 Promega Corporation Prevention and treatment of autoimmune disease with luminally administered polyclonal antibodies
EP1246848A1 (en) 1999-12-27 2002-10-09 University Of Manitoba GENETIC VACCINES FOR THE PRODUCTION OF CHICKEN EGG-YOLK ANTIBODIES AGAINST ENTEROTOXIGENIC i ESCHERICHIA COLI /i AND OTHER PATHOGENS
WO2002003788A2 (en) 2000-07-06 2002-01-17 Deltagen, Inc. Transgenic mice containing targeted phosphatase gene disruptions
DK1687066T3 (da) * 2003-11-14 2012-11-26 Brigham & Womens Hospital Fremgangsmåder til immunmodulering
JP4886983B2 (ja) * 2004-12-09 2012-02-29 アサマ化成株式会社 抗体を含有する機能性組成物
BRPI0716319A8 (pt) 2006-10-25 2019-02-05 Aovatechnologies Inc método para reduzir a absorção de fosfato em um indivíduo animal humano ou não-humano correndo o risco de desenvolver ou que desenvolveu hiperfosfatomia e método para reduzir os efeitos colaterais da terapia de vitamina d em um ser humano
CA2667563A1 (en) * 2006-10-26 2008-05-02 Wisconsin Alumni Research Foundation Methods of reducing phosphate absorption

Also Published As

Publication number Publication date
US20100233184A1 (en) 2010-09-16
WO2008051977A2 (en) 2008-05-02
US8877198B2 (en) 2014-11-04
BRPI0716320A2 (pt) 2014-02-25
CA2667613A1 (en) 2008-06-05
JP5701504B2 (ja) 2015-04-15
EP2076543A2 (en) 2009-07-08
AU2007309026B2 (en) 2013-09-12
EP2076543B1 (en) 2016-01-27
AU2007309026A1 (en) 2008-05-02
CN101583627A (zh) 2009-11-18
EP2081963A2 (en) 2009-07-29
WO2008051977A8 (en) 2009-05-28
AU2007325459A1 (en) 2008-06-05
WO2008067084A3 (en) 2008-07-31
CN101595131A (zh) 2009-12-02
JP2010508281A (ja) 2010-03-18
BRPI0716317A2 (pt) 2014-02-25
WO2008067084A2 (en) 2008-06-05
WO2008051977A3 (en) 2008-07-03
CA2667563A1 (en) 2008-05-02
JP2014237591A (ja) 2014-12-18
US20100143385A1 (en) 2010-06-10
JP2010508282A (ja) 2010-03-18

Similar Documents

Publication Publication Date Title
Unger et al. Vitamin D status in a sunny country: where has the sun gone?
Freeman et al. Performance evaluation of four 25-hydroxyvitamin D assays to measure 25-hydroxyvitamin D2
Morkbak et al. Holotranscobalamin remains unchanged during pregnancy. Longitudinal changes of cobalamins and their binding proteins during pregnancy and postpartum
Stenvinkel et al. Metabolic changes in summer active and anuric hibernating free-ranging brown bears (Ursus arctos)
BRPI0716317A8 (pt) método para reduzir a absorção de fosfato em um indivíduo animal humano ou não-humano e método para reduzir a absorção de fosfato em um indivíduo humano
Szkup et al. Analysis of relations between the level of Mg, Zn, Ca, Cu, and Fe and depressiveness in postmenopausal women
Ko et al. Dietary beet pulp decreases taurine status in dogs fed low protein diet
Dawson et al. Sulphate in pregnancy
Cupisti et al. Vitamin D status and cholecalciferol supplementation in chronic kidney disease patients: an Italian cohort report
Torres et al. Iodine nutritional status of women in their first trimester of pregnancy in Catalonia
Kasatkina et al. Gestational hypothyroxinemia and cognitive function in offspring
BRPI0716319A8 (pt) método para reduzir a absorção de fosfato em um indivíduo animal humano ou não-humano correndo o risco de desenvolver ou que desenvolveu hiperfosfatomia e método para reduzir os efeitos colaterais da terapia de vitamina d em um ser humano
Kim et al. Differences in the susceptibility to cadmium-induced renal tubular damage and osteoporosis according to sex
Iqbal et al. Oxytocin induced oxidative stress in lactating Bubalis bubalis (Nili Ravi)
Boykin et al. Digestibility of black soldier fly larvae (Hermetia illucens) fed to leopard geckos (Eublepharis macularius)
BRPI0807601B8 (pt) método para identificação de um paciente que esteja em risco com relação ao desenvolvimento de um distúrbio na tireoide e uso de um agente depletivo de linfócitos
Gonzalez-Uarquin et al. Interrelationship of myo-inositol pathways with systemic metabolic conditions in two strains of high-performance laying hens during their productive life span
August et al. Effect of maternal antioxidant supplementation and/or exercise practice during pregnancy on postnatal overnutrition induced by litter size reduction: Brain redox homeostasis at weaning
Rockell et al. Vitamin D insufficiency in New Zealanders during the winter is associated with higher parathyroid hormone concentrations: implications for bone health?
ATE449332T1 (de) Alterungsbiomarker
Gajęcka et al. Concentration of zearalenone, alpha-zearalenol and beta-zearalenol in the myocardium and the results of isometric analyses of the coronary artery in prepubertal gilts
Heger et al. Individual response of growing pigs to sulphur amino acid intake
BR112019020008A2 (pt) métodos para identificar predisposição ao declínio cognitivo e agentes para atenuar ou previnir o declínio cognitivo ou melhorar a capacidade cognitiva
Omonkhua et al. Effects of vitamin C on kidney and bone of rats exposed to low doses of cadmium
Mukai et al. Effect of fructose on the phosphorylation of AMP‐activated protein kinase and acetyl‐CoA carboxylase in HepG2 cells stimulated with placental lactogen

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]